Comparable stake leader
Jonathan H. Kaufman
SEC ownership of LIPELLA PHARMACEUTICALS INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001347242.
Disclosed value leader
Jonathan H. Kaufman
Comparable rows
4/11
Latest evidence
03 Apr 2025
- Public ticker
- LIPO on OTC
- Parsed ownership sources
-
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Jonathan H. Kaufman
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 11
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Jonathan H. Kaufman
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Apr 2025
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001347242
- Issuer location
- Pittsburgh, PA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of LIPELLA PHARMACEUTICALS INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Jonathan H. Kaufman
Disclosed value leader
Jonathan H. Kaufman
Comparable rows
4/11
Latest evidence
03 Apr 2025
3/4/5
13D/G
Lead comparable stake: 4.9%
7 rows are not safely comparable across share classes.
13D/G row: Jonathan H. Kaufman
Showing 1-8 of 11 holder rows.
Quick read
Jonathan H. Kaufman leads the comparable SEC ownership view at 4.9%.
4 of 11 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Jonathan H. Kaufman's linked filing trail.
Comparable ownership
Top 4
Jonathan H. Kaufman
4.9%
SABBY MANAGEMENT, LLC
4.9%
Michael B. Chancellor
4.8%
Leaf Huang
2.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 11 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Jonathan H. Kaufman |
3/4/5
13D/G
President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors, Director, 10%+ Owner
|
4.9%
Reported 13D/G
· 07 Apr 2025
|
$682,226
898,849 shares
|
— | 03 Apr 2025 |
| SABBY MANAGEMENT, LLC |
13D/G
|
4.9%
Reported 13D/G
· 31 Dec 2024
|
$18,701
60,325 shares
|
$0 | 31 Dec 2024 |
| Michael B. Chancellor |
3/4/5
13D/G
Chief Medical Officer, Director, 10%+ Owner
|
4.8%
Reported 13D/G
· 07 Apr 2025
|
$605,657
957,637 shares
mixed-class rows
|
— | 15 Mar 2024 |
| Leaf Huang |
13D/G
|
2.7%
Reported 13D/G
· 31 Mar 2025
|
$179,857
69,443 shares
|
$0 | 31 Mar 2025 |
| Douglas Johnston |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
—
100,000 shares
mixed-class rows
|
— | 15 Mar 2024 |
| Byong Kim |
3/4/5
Director
|
—
denominator unverified
|
—
25,000 shares
|
— | 15 Mar 2024 |
| Daniel R. Cohen |
3/4/5
Director
|
—
denominator unverified
|
—
25,000 shares
|
— | 15 Mar 2024 |
| David S. Battleman |
3/4/5
Director
|
—
denominator unverified
|
—
25,000 shares
|
— | 16 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
No eligible buy or sell activity is available for this window. No eligible Buy or Sell transactions are available in this dataset since 22 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-9 of 9 reporting-owner rows connected to LIPELLA PHARMACEUTICALS INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
9
Largest Forms 3/4/5 holder
Jonathan H. Kaufman
Net 12M change
$0
Latest report
03 Apr 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jonathan H. Kaufman | President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors, Director, 10%+ Owner | $682,226 | Filing P/S | 03 Apr 2025 | ||
| Michael B. Chancellor | Chief Medical Officer, Director, 10%+ Owner | $605,657 | Mixed | 15 Mar 2024 | ||
| David S. Battleman | Director | Mixed | 16 Jun 2023 | |||
| Naoki Yoshimura | Director | Mixed | 15 Mar 2024 | |||
| Douglas Johnston | Chief Financial Officer | Mixed | 15 Mar 2024 | |||
| Lori Birder | Director | Mixed | 15 Mar 2024 | |||
| Byong Kim | Director | Mixed | 15 Mar 2024 | |||
| Ryan Pruchnic | Director | Mixed | 15 Mar 2024 | |||
| Daniel R. Cohen | Director | Mixed | 15 Mar 2024 |
Recent insider transactions for LIPELLA PHARMACEUTICALS INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.